

INFORME DE BÚSQUEDA DE PATENTES				
N° de solicitud: NC2017/0002166				
CRITERIOS PARA LA BÚSQUEDA (Anexar pantallazo o reporte en PDF, junto con los boléanos utilizados*. Para el caso de secuencias, anexar alineamientos)				
PALABRAS CLAVE UTILIZADAS		Il2 fusion protein, il-2/il-2R, (GGGS)4 linker fusion protein		
CLASIFICACIONES UTILIZADAS PARA LA BÚSQUEDA		CIP: A61K 38/00, C07K 14/55.		
DOCUMENTOS CONSIDERADOS RELEVANTES (documentos patentes, literatura no patente, etc...)				
Informes/Base de datos	N° de solicitud/ Autor**	Fecha de Publicación/ Presentación (DD/MM/AAAA)	Reiv. afectadas (Con indicación, si procede, de las partes relevantes o números de secuencias)	Categorías especiales de los documentos citados***
SIPI	NA			
ISA(EPO) EPO	Puskas et al.	23/06/2011	8 y 9	Y
	Melder et al.	1/06/2005	NA	A
	Wilkinson et al.	01/09/2007	8 y 9	Y
ISA(EPO)	WO2014/023752	13/02/2014	NA	A
	Millington et al.	1/04/2012	NA	A
	Stoklasek et al.	1/11/2006	NA	A
ISA(EPO) EPO NCBI (SEQ ID NO:26, 27, 36, 37, 57, 59 y 62)	wo2011/123683	6/10/2011	NA	Y
*** Categorías especiales de documentos citados:				
“A” documento que define el estado general de la técnica no considerado como particularmente relevante. “E” solicitud de patente o patente anterior pero publicada en la fecha de presentación internacional o en fecha posterior. “P” documento publicado antes de la fecha de presentación internacional pero con posterioridad a la fecha de prioridad reivindicada.		“X” documento particularmente relevante; la invención reivindicada no puede considerarse nueva o que implique una actividad inventiva por referencia al documento aisladamente considerado. “Y” documento particularmente relevante; la invención reivindicada no puede considerarse que implique una actividad inventiva cuando el documento se asocia a otro u otros documentos de la misma naturaleza, cuya combinación resulta evidente para un experto en la materia.		
**** Indicar entre paréntesis la Autoridad que realizó la búsqueda o el informe preliminar Ejs: EPO, JP, INAPI.				

Literatura no patente **Se incluye entre otros, toda la referencia de la literatura no patente.	Wilkinson, I. R., Ferrandis, E., Artymiuk, P. J., Teillot, M., Soulard, C., Touvay, C., ... Ross, R. J. (2007). A ligand-receptor fusion of growth hormone forms a dimer and is a potent long-acting agonist. <i>Nature Medicine</i>, 13, 1108. Retrieved from http://dx.doi.org/10.1038/nm1610 Puskas, J., Skrombolas, D., Sedlacek, A., Lord, E., Sullivan, M., & Frelinger, J. (2011). Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases. <i>Immunology</i>, 133(2), 206–220. http://doi.org/10.1111/j.1365-2567.2011.03428.x
---	---

Fecha del reporte de búsqueda:	06/04/2018
--------------------------------	------------

Buscador	Ncbi-nr
query	Seq 2

Description	Max score	Total score	Query cover	E value	Ident	Accession
Interleukin 2 [Homo sapiens]	273	273	100%	2e-92	100%	AAH66254.1
interleukin-2 precursor [Homo sapiens]	272	272	100%	2e-92	100%	NP_000577.2
PREDICTED: interleukin-2 [Gorilla gorilla gorilla]	272	272	100%	2e-92	100%	XP_004040401.1
Chain A, Crystal Structure Of Human Interleukin-2	271	271	100%	3e-92	100%	1M47_A
interleukin 2 [Homo sapiens]	271	271	100%	3e-92	100%	AAA59140.1
interleukin 2	270	270	100%	1e-91	99%	1009281A
Chain A, Structure Of A 60 Nm Small Molecule Bound To A Hot Spot On Il-2	270	270	99%	1e-91	100%	1PY2_A
interleukin 2 [synthetic construct]	271	271	100%	2e-91	100%	CAP05187.1
unnamed protein product [Vector pLTp35]	269	269	99%	2e-91	100%	SJI88000.1
PREDICTED: interleukin-2 [Nomascus leucogenys]	270	270	100%	3e-91	99%	XP_003271397.1

Buscador	Ncbi-nr
query	Seq 7

Description	Max score	Total score	Query cover	E value	Ident	Accession
unnamed protein product [Mammalian expression vector pMET7hIL-2Ralpha]	459	459	100%	4e-163	100%	SJI87162.1
interleukin-2 receptor subunit alpha isoform 1 precursor [Homo sapiens]	459	459	100%	9e-163	100%	NP_000408.1
interleukin-2 receptor precursor [Homo sapiens]	457	457	100%	1e-162	99%	AAA59142.1
unnamed protein product [Homo sapiens]	456	456	100%	7e-162	99%	BAG36576.1
interleukin 2 receptor, alpha chain precursor variant [Homo sapiens]	456	456	100%	1e-161	99%	BAD97033.1
interleukin 2 receptor	456	456	100%	1e-161	99%	1101409A
Chain I, Crystal Structure Of The Fab Fragment Of Therapeutic Antibody Basiliximab In Cor	453	453	100%	2e-161	99%	3IU3_I
Chain B, Structure Of Interleukin-2 With Its Alpha Receptor	452	452	99%	4e-161	100%	1Z92_B
Chain D, Cytokine Receptor Complex	450	450	99%	4e-160	99%	2B5I_D
interleukin-2 receptor subunit alpha precursor [Pan troglodytes]	450	450	100%	2e-159	98%	NP_001030597.1

Buscador	Ncbi-PATENTED SEQUENCES
query	Seq 26, 27, 36, 37, 57, 59 y 62

QUERY	Description	Query cover	E value	Ident
26	Sequence 45 from patent US 8734774	100%	0	97%
26	Sequence 48 from patent US 8734774	100%	0	95%
26	Sequence 46 from patent US 8734774	100%	0	95%
26	Sequence 49 from patent US 8734774	100%	0	95%
26	Sequence 47 from patent US 8734774	100%	0	95%
26	Sequence 50 from patent US 8734774	100%	0	93%
26	Sequence 16 from patent US 9556269	60%	7.00E-165	100%
26	Sequence 9337 from patent US 7235358	61%	8.00E-165	99%
26	Sequence 17 from patent US 9784728	61%	3.00E-163	98%
26	Sequence 2 from Patent EP 0162699	61%	2.00E-162	97%
27	Sequence 45 from patent US 8734774	100%	0	96%
27	Sequence 48 from patent US 8734774	100%	0	95%
27	Sequence 49 from patent US 8734774	100%	0	95%
27	Sequence 46 from patent US 8734774	100%	0	95%
27	Sequence 47 from patent US 8734774	100%	0	95%
27	Sequence 50 from patent US 8734774	100%	0	93%
27	Sequence 9337 from patent US 7235358	58%	3.00E-165	99%
27	Sequence 16 from patent US 9556269	57%	3.00E-165	100%
27	Sequence 17 from patent US 9784728	58%	1.00E-163	98%
27	Sequence 2 from Patent EP 0162699	58%	1.00E-162	97%
37	Sequence 31 from patent US 8734774	100%	0	96%
37	Sequence 32 from patent US 8734774	100%	0	96%
37	Sequence 33 from patent US 8734774	100%	0	94%
37	Sequence 34 from patent US 8734774	100%	0	94%
37	Sequence 38 from patent US 8734774	100%	0	93%
37	Sequence 36 from patent US 8734774	100%	0	94%
37	Sequence 37 from patent US 8734774	100%	0	94%
37	Sequence 35 from patent US 8734774	100%	0	94%
37	Sequence 9 from patent US 8124084	54%	5.00E-162	99%
37	Sequence 45 from patent US 8734774	100%	1.00E-132	54%

57	Sequence 32 from patent US 8734774	100%	0	96%
57	Sequence 34 from patent US 8734774	100%	0	94%
57	Sequence 37 from patent US 8734774	100%	0	93%
57	Sequence 36 from patent US 8734774	100%	0	93%
57	Sequence 38 from patent US 8734774	100%	0	93%
57	Sequence 35 from patent US 8734774	100%	0	93%
57	Sequence 31 from patent US 8734774	98%	0	96%
57	Sequence 33 from patent US 8734774	98%	0	94%
57	Sequence 9 from patent US 8124084	53%	2.00E-161	99%
57	Sequence 45 from patent US 8734774	98%	2.00E-132	54%
59	Sequence 49 from patent US 8734774	100%	0	95%
59	Sequence 47 from patent US 8734774	100%	0	95%
59	Sequence 45 from patent US 8734774	97%	0	96%
59	Sequence 48 from patent US 8734774	97%	0	95%
59	Sequence 46 from patent US 8734774	97%	0	95%
59	Sequence 50 from patent US 8734774	97%	0	93%
59	Sequence 16 from patent US 9556269	55%	9.00E-165	100%
59	Sequence 9337 from patent US 7235358	56%	9.00E-165	99%
59	Sequence 17 from patent US 9784728	56%	4.00E-163	98%
59	Sequence 2 from Patent EP 0162699	56%	3.00E-162	97%
62	Sequence 45 from patent US 8734774	100%	0	96%
62	Sequence 48 from patent US 8734774	100%	0	95%
62	Sequence 49 from patent US 8734774	100%	0	95%
62	Sequence 46 from patent US 8734774	100%	0	95%
62	Sequence 47 from patent US 8734774	100%	0	95%
62	Sequence 50 from patent US 8734774	100%	0	92%
62	Sequence 16 from patent US 9556269	60%	5.00E-163	99%
62	Sequence 9337 from patent US 7235358	61%	5.00E-163	98%
62	Sequence 17 from patent US 9784728	61%	3.00E-161	97%
62	Sequence 2 from Patent EP 0162699	61%	1.00E-160	96%